Key facts
- It has raised $101.4M; the latest was Later Stage VC ($100.0M) in Jun 2024.
- Notable investors include 8VC, New Enterprise Associates, F-Prime Capital, University of Oxford, Oxford Science Enterprises — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Amber Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Amber Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amber Therapeutics
Developer of a bioelectronic platform designed to generate novel, neuromodulation therapies. The company focuses on the peripheral instead of the central nervous system to develop novel bioelectrical therapies for treating mixed urinary incontinence by targeting disease areas and adding closed-loop intelligence, enabling industry professionals to improve clinical efficacy and outcomes.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 45
- Website
- amber-tx.com/
- Ownership
- Privately Held (backing)
Amber Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amber Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amber Therapeutics in its N-PORT filings yet. We sweep new filings monthly.